Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.
This pharma company is a major holding within XLV, but worth owning itself. The company just reported Q2 earnings, with total net revenues beating, bolstered by 10.2% sales growth. To replace its blockbuster drug, Humira, AbbVie launched Skyrizi which boasts global sales of $5.5 billion, and Rinvoq (global sales of over $2.5 billion). AbbVie's overall sales growth was 10.2%.

Here are the Canadian companies listed on Stockchase who are reporting earnings this week: 🛢Basic Materials ⚡ Energy 🏛 Financials 💻 Technology 👨⚕️ Healthcare 🚚 Industrials 🛍 Consumer 💡 Utilities Use this list wisely to identify buying opportunities.Happy trading !!! read more
Build your watch list
Sign in to track investments
you care about